{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:11:22Z","timestamp":1760145082795,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The Mayo Score [MS], endoscopic Mayo Score [eMS] and the Ulcerative Colitis Index of Severity [UCEIS] are employed in the assessment of ulcerative colitis [UC] severity. This study compared the aforementioned indices in terms of predictory value for response to remission induction treatment with anti-TNF and anti-integrin biologics. Methods: A total of 38 patients were retrospectively evaluated in the study, 23 male and 15 female, aged 18\u201374 years old who had undergone a total of 53 biological therapy courses with either infliximab [IFX] or vedolizumab [VDZ] at the Department of Gastroenterology of the Medical University of \u0141\u00f3d\u017a. The clinical and endoscopic activity of UC was assessed at the outset of biological therapy and the 14th week remission induction assessment juncture. Results: The study analyzed 19 IFX and 34 VDZ treatment courses. The response rate of patients receiving IFX reached 73.67% and the response rate was 58.82% for VDZ. The mean MS, eMS and UCEIS improved among all patient groups: 8.316 \u00b1 1.974 to 4.158 \u00b1 2.218 (p &lt; 0.05), 2.632 \u00b1 0.597 to 1.790 \u00b1 0.713 (p &lt; 0.05) and 4.790 \u00b1 1.745 to 3.000 \u00b1 1.453 (p &lt; 0.05) for IFX, 7.088 \u00b1 2.234 to 3.618 \u00b1 2.412 (p &lt; 0.05), 2.706 \u00b1 0.524 to 1.677 \u00b1 1.065 (p &lt; 0.05) and 4.235 \u00b1 1.350 to 2.735 \u00b1 1.880 (p &lt; 0.05) for VDZ. Conclusions: The outcome assessment in induction treatment of UC includes clinical data and endoscopic evaluation. Severity of inflammatory lesion activity according to the eMS and UCEIS indices correlates with the overall disease presentation as evaluated with MS. The UCEIS provides an overall better predictor for biological induction treatment when compared with the eMS in both patient groups, particularly in those receiving VDZ. It provides a promising alternative to the eMS and can be employed for both initial disease severity assessment as well as for treatment response monitoring.<\/jats:p>","DOI":"10.3390\/jcm13123455","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T06:23:11Z","timestamp":1718259791000},"page":"3455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Utility of Disease Activity Indices in Predicting Short-Term Response to Biologics in Patients with Ulcerative Colitis"],"prefix":"10.3390","volume":"13","author":[{"given":"Filip","family":"Romaniuk","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Medical University of \u0141\u00f3d\u017a, 90-419 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Franus","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Medical University of \u0141\u00f3d\u017a, 90-419 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Sobolewska-W\u0142odarczyk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Medical University of \u0141\u00f3d\u017a, 90-419 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-3721","authenticated-orcid":false,"given":"Anita","family":"G\u0105siorowska","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Medical University of \u0141\u00f3d\u017a, 90-419 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis.-A-Mon."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr. Rev. Musculoskelet. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MEG.0000000000000532","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"28","author":"Rossi","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (stride): Determining therapeutic goals for treat-to-target","volume":"110","author":"Sandborn","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/pg.2023.125882","article-title":"Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish national consultant in gastroenterology","volume":"18","author":"Eder","year":"2023","journal-title":"Gastroenterol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","first-page":"e17729","article-title":"Efficacy and safety of vedolizumab in management of moderate to severe ulcerative colitis: A systematic review","volume":"13","author":"Bhandari","year":"2021","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.gtc.2020.08.002","article-title":"Biologic therapy for ulcerative colitis","volume":"49","author":"Bhattacharya","year":"2020","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"A4\u03b27 integrin mediates lymphocyte binding to the mucosal vascular addressin madcam-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Luzentales-Simpson, M., Pang, Y.C., Zhang, A., Sousa, J.A., and Sly, L.M. (2021). Vedolizumab: Potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.612830"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2165\/00019053-200624080-00006","article-title":"Costs of inflammatory bowel disease in Germany","volume":"24","author":"Stark","year":"2006","journal-title":"PharmacoEconomics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5114\/pg.2017.66324","article-title":"Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland","volume":"1","author":"Kawalec","year":"2017","journal-title":"Gastroenterol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/apt.15889","article-title":"Healthcare use, work loss and total costs in incident and prevalent crohn\u2019s disease and ulcerative colitis: Results from a nationwide study in Sweden","volume":"52","author":"Khalili","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pakdin, M., Zarei, L., Bagheri Lankarani, K., and Ghahramani, S. (2023). The cost of illness analysis of inflammatory bowel disease. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-02648-z"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Haga, K., Shibuya, T., Osada, T., Sato, S., Fukuo, Y., Kobayashi, O., Yamada, T., Asaoka, D., Ito, K., and Nomura, K. (2022). Early clinical remission is a predictor of long-term remission with the use of vedolizumab for ulcerative colitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102526"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1097\/MIB.0000000000000474","article-title":"Extent of early clinical response to infliximab predicts long-term treatment success in active ulcerative colitis","volume":"21","author":"Murthy","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s10620-016-4089-2","article-title":"Long-term follow-up of patients treated with infliximab for ulcerative colitis: Predictive factors of response\u2014An observational study","volume":"61","author":"Aceituno","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/ecco-jcc\/jjw067","article-title":"Long-term outcome of patients with ulcerative colitis and primary non-re-sponse to infliximab","volume":"10","author":"Papamichael","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640620977405","article-title":"Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study","volume":"9","author":"Festa","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"998470","DOI":"10.3389\/fimmu.2022.998470","article-title":"Identification and exploration of pharmacological pyroptosis-related biomarkers of ulcerative colitis","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"03000605231184046","DOI":"10.1177\/03000605231184046","article-title":"Association with controlling nutritional status score and disease activity of ulcerative colitis","volume":"51","author":"Lian","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4292\/wjgpt.v10.i2.50","article-title":"Nutritional status as a predictor of hospitalization in inflammatory bowel disease: A Review","volume":"10","author":"Rocha","year":"2019","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s10620-012-2081-z","article-title":"Association of age at diagnosis and ulcerative colitis phenotype","volume":"57","author":"Quezada","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40266-022-00943-0","article-title":"Ulcerative colitis in adulthood and in older patients: Same disease, same outcome, same risks?","volume":"39","author":"Fries","year":"2022","journal-title":"Drugs Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2022-327533","article-title":"Early manage-ment of acute severe UC in the biologics era: Development and international validation of a prognostic clinical index to predict steroid response","volume":"72","author":"Adams","year":"2022","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Laredo, V., Gargallo-Puyuelo, C.J., and Gomoll\u00f3n, F. (2022). How to choose the biologic therapy in a bio-na\u00efve patient with inflammatory bowel disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030829"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00384-022-04098-7","article-title":"Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: Results from the prospective, observational EPICOL study","volume":"37","author":"Schmidt","year":"2022","journal-title":"Int. J. Color. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/gastro\/goab022","article-title":"Cut-off value of ulcerative colitis endoscopic index of severity (UCEIS) score for predicting the need for pouch construction in ulcerative colitis: Results of a multicenter study with long-term follow-up","volume":"9","author":"Xu","year":"2021","journal-title":"Gastroenterol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ecco-jcc\/jjv210","article-title":"The ulcerative colitis endo-scopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score","volume":"10","author":"Ikeya","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/gastro\/gox016","article-title":"Ulcerative colitis endoscopic index of severity (UCEIS) versus Mayo endoscopic score (MES) in guiding the need for colectomy in patients with acute severe colitis","volume":"6","author":"Xie","year":"2017","journal-title":"Gastroenterol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjv047","article-title":"Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis","volume":"9","author":"Corte","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_35","first-page":"534","article-title":"Role of ulcerative colitis endoscopic index of severity (UCEIS) versus Mayo endoscopic Subscore (MES) in predicting patients\u2032 response to biological therapy and the need for colectomy","volume":"102","author":"Variola","year":"2020","journal-title":"Digestion"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lers.2021.04.003","article-title":"Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis","volume":"4","author":"Chen","year":"2021","journal-title":"Laparosc. Endo-Scopic Robot. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e35799","DOI":"10.1097\/MD.0000000000035799","article-title":"The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab","volume":"102","author":"Yan","year":"2023","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/ibd\/izad074","article-title":"Predicting endoscopic improvement in ulcerative colitis using the ulcerative colitis severity index","volume":"30","author":"Wong","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/12\/3455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:57:57Z","timestamp":1760108277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/12\/3455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13123455"],"URL":"https:\/\/doi.org\/10.3390\/jcm13123455","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}